-Reuters
SVB Leerink Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $50
SVB Leerink analyst Joseph Schwartz maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $35 to $50.